Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 10, 2012, Pages 1799-1807

  Molenaar, Pascal J ^a   Dinkelaar, Jasper ^a   Leyte, Anja ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Anti Xa activity; BAY 59 7939; Coagulation assays; Rivaroxaban; Thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR 10A; RIVAROXABAN; THROMBIN;

ACCURACY; ARTICLE; ASSAY; BLOOD CLOTTING; BLOOD DONOR; CLINICAL LABORATORY; CONTROLLED STUDY; DRUG MONITORING; HEMOSTASIS; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LABORATORY DEVICE; MEASUREMENT; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME;

ANTICOAGULANTS; BLOOD CHEMICAL ANALYSIS; BLOOD COAGULATION TESTS; BLOOD DONORS; CALIBRATION; FACTOR XA; HUMANS; MORPHOLINES; THIOPHENES; THROMBIN;

EID: 84867826077     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0055     Document Type: Article

References (21)

1. Perzborn E, Kubitza D, Misselwitz F. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie 2007;27:282-9.
2. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453-61.
3. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011;9(Suppl 1):12-9.
4. Altman R, Vidal HO. Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J 2011;27:9-12.
5. Favaloro EJ, Lippi G. Editorial. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med 2011;49:755-7.
6. Samama MM, Guinet C. Laboratory assessments of new anticoagulants. Clin Chem Lab Med 2011;49:761-72.
7. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-9.
8. Samama MM, Martinoli JL, Le Flem L, Guinet C, Plu-Bureau M, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
9. Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxabantreated patients: results of an in vitro study. J Thromb Haemost 2011;9:226-8.
10. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010;32:673-9.
11. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-21.
12. Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007;33:515-23.
13. Green L, Lawrie AS, Patel S, Hossain F, Chitolie A, Mackie IJ, et al. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol 2010;151:469-76.
14. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617-24.
15. Oudemans-van Straaten HM, van Schilfgaarde M, Molenaar PJ, Wester JP, Leyte A. Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates. Crit Care 2009;13:R193.
16. Salvagno GL, Berntorp E. Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective. Semin Thromb Hemost 2010;36:780-90.
17. Wielders S, Mukherjee M, Michiels J, Rijkers DT, Cambus JP, Knebel RW, et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper-and hypocoagulability. Thromb Haemost 1997;77:629-36.
18. Wilkens M. [Endogenous thrombin potential in practical use]. Hamostaseologie 2011;31:88-93. German.
19. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011;127:457-65.
20. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104:1263-71.
21. Wielders SJ, Beguin S, Hemker HC, Lindhout T. Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available. Arterioscler Thromb Vasc Biol 2004;24:1138-42.